key: cord-0756041-gdcqu3nb
authors: Li, Can; Chen, Yanxia; Zhao, Yan; Lung, David Christopher; Ye, Zhanhong; Song, Wenchen; Liu, Fei-Fei; Cai, Jian-Piao; Wong, Wan-Man; Yip, Cyril Chik-Yan; Chan, Jasper Fuk-Woo; To, Kelvin Kai-Wang; Sridhar, Siddharth; Hung, Ivan Fan-Ngai; Chu, Hin; Kok, Kin-Hang; Jin, Dong-Yan; Zhang, Anna Jinxia; Yuen, Kwok-Yung
title: Intravenous injection of COVID-19 mRNA vaccine can induce acute myopericarditis in mouse model
date: 2021-08-18
journal: Clin Infect Dis
DOI: 10.1093/cid/ciab707
sha: 4cdd55a767f78a6edbe8abe9a685aa57a48c327e
doc_id: 756041
cord_uid: gdcqu3nb

BACKGROUND: Post-vaccination myopericarditis is reported after immunization with COVID-19 mRNA-vaccines. The effect of accidental intravenous injection of this vaccine on the heart is unknown. METHODS: We compared the clinical manifestations, histopathological changes, tissue mRNA expression and serum levels of cytokine/chemokine in Balb/c mice at different time points after intravenous(IV) or intramuscular(IM) vaccine injection with normal saline(NS) control. RESULTS: Though significant weight loss and higher serum cytokine/chemokine levels were found in IM group at 1 to 2 days post-injection(dpi), only IV group developed histopathological changes of myopericarditis as evidenced by cardiomyocyte degeneration, apoptosis and necrosis with adjacent inflammatory cell infiltration and calcific deposits on visceral pericardium, while evidence of coronary artery or other cardiac pathologies was absent. SARS-CoV-2 spike antigen expression by immunostaining was occasionally found in infiltrating immune cells of the heart or injection site, in cardiomyocytes and intracardiac vascular endothelial cells, but not skeletal myocytes. The histological changes of myopericarditis after the first IV-priming dose persisted for 2 weeks and were markedly aggravated by a second IM- or IV-booster dose. Cardiac tissue mRNA expression of IL-1β, IFN-β, IL-6 and TNF-α increased significantly from 1dpi to 2dpi in IV but not IM group, compatible with presence of myopericarditis in IV group. Ballooning degeneration of hepatocytes was consistently found in IV group. All other organs appeared normal. CONCLUSIONS: This study provided in-vivo evidence that inadvertent intravenous injection of COVID-19 mRNA-vaccines may induce myopericarditis. Brief withdrawal of syringe plunger to exclude blood aspiration may be one possible way to reduce such risk.

Safe and effective whole-population vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the only long term solution to the ongoing Coronavirus Disease 2019 (COVID-19) pandemic [1] , which has caused about 200 million cases of COVID-19 globally and over 4 million deaths by 17 July 2021 [2] . However the one-dose vaccination rate in US and UK was only 54.9% and 67.8% respectively as of 10 July 2021 [3] .

Vaccine hesitancy among the general public is a significant problem, and is partially driven by the apprehension of rare but potentially severe side effects of these rapidly developed novel vaccines. An example of such a side effect is myopericarditis following mRNA COVID-19 vaccines, which has a crude incidence of 40.6 cases per million second doses administered to males aged 12−29 years [4] . The pathogenesis of this unexpected complication remains elusive.

The World Health Organization (WHO) [5] and Centers for Disease Control and Prevention (CDC) [6] no longer recommend aspiration of syringe plunger during intramuscular injections, especially during vaccination when a rapid injection of a small volume may reduce discomfort [6] . However, a self-reporting study of registered nurses showed that 40% reported blood aspiration at least once, and 4% reported blood aspiration 13 times or more during intramuscular injection. The finding suggests that inadvertent intravenous injection of vaccine is possible [7] . Recently, inadvertent intravenous injection of adenovirus-vector based COVID-19 vaccine was implicated to trigger platelet-adenovirus aggregates taken up by spleen which mountedl B cell response of binding antibodies against platelets [8] . In this study, we investigated the differences in the cardiac pathology induced by intravenous(IV) or 

Female Balb/c (substrain OlaHsd) mice at age of 6-8 weeks were obtained from the Centre for Comparative Medicine Research of The University of Hong Kong and kept in Biosafety Level (BSL)-2 animal laboratory with 12-hour light-dark cycle and free access to water and diet. The animals were randomly assigned to three groups for the administration of IV or IM COVID-19 mRNA vaccine, or normal saline(NS) control( Figure 1A ). COVID-19 mRNA vaccine (BNT162b2 lot number 1B004A, BioNTech, Germany) dose of 0.25ug per gram of body weight was injected (about 5µg in 50µL per mouse; dose according to an immunogenicity study) via tail vein or thigh muscle, respectively, with the control group having the same volume of NS [9] . Another group of male mice was subsequently tested by the same protocol after preliminary positive results. The mice were monitored by clinical signs and body weight changes for 14 days. Necropsies were performed at 1, 2, 7 and 14 days post-injection(dpi). Organs and blood were sampled for histological and real-time quantitative RT-PCR, or cytokine/chemokine levels respectively. A group of mice received a second boosting dose 14 days after the first priming dose and examined at 2dpi after boosting. The procedures for animal experiments in this study were approved by the HKU Committee on the Use of Live Animals in Teaching and Research.

Formalin-fixed and paraffin-embedded mouse heart, lung, liver, spleen, kidney and brain tissues were cut into 4µm sections and stained with hematoxylin and eosin(H&E) for histopathological examination. Immunohistochemistry staining for leukocyte biomarkers, SARS-CoV-2 spike receptor binding domain (S-RBD) and terminal deoxynucleotidyl transferase dUTP nick end labelling(TUNEL) were performed as we described A c c e p t e d M a n u s c r i p t 7 previously [10] . Primary antibodies including rabbit anti-SARS-CoV-2 S-RBD used in our previous study [11] , rabbit anti-mouse CD45, CD68, or CD3(Abcam) were used in this study. DNA fragmentation in cardiomyocytes was labelled using Click-iT® Plus TUNEL assay kit(Thermo Fisher Scientific) for the detection of apoptosis [10] . The slides were mounted and examined under light microscope. Representative images were captured with Olympus BX53 semi-motorised fluorescence microscope. The measurement of cytokine and chemokines mRNA expression levels in different tissues, serum cytokine/chemokine levels, serum troponin levels, and the statistical analysis(Supplementary method).

Groups of female Balb/c mice at age of 6-8 week were given BNT162b2 COVID-19 mRNA vaccine either IV or IM, or same volume of NS( Figure 1A) . None of the animals showed clinical signs of lethargy, ruffled furs, hunched back posture, and rapid breathing throughout the course of observation. Significant decrease in body weight was observed in IM mRNA vaccine group(mean 3.6%±2.1%) starting from 1dpi; animals recovered their initial weight at 7 dpi( Figure 1B ). Autopsy at 1 to 2dpi showed white patches over the visceral pericardium in 37.5%(1dpi, n=8) to 38.5%(2dpi, n=13) of IV vaccine group but none in the IM vaccine or NS control groups( Figure 1C and 1D A c c e p t e d M a n u s c r i p t 8

Low power scanning of heart sections showed blue stained thickened visceral pericardium over the right atrium and ventricle at 1dpi of IV vaccine, which became more prominent at 2dpi (Figure 2A ). At higher magnification, calcific deposits were seen in these thickened pericardial tissues( Figure 2D ). Multifocal pericardial and myocardial inflammatory cell infiltrates and interstitial oedema were also observed( Figure 2C ). Frequent foci of cardiomyocytes had degenerative changes as evident by the loss of the normal pattern of cross striation and occasionally sarcoplasmic vacuolation, and necrotic changes as distinguished by the attainment of a homogenous appearance, sarcoplasmic fragmentation, or pyknosis( Figure 2E ). These changes were significantly more frequent in the IV vaccine group at 2dpi (Table 1) , and more often in the right atrium and right ventricles of the affected animals and especially prominent on their pericardial side. Immunohistochemical staining with anti-CD45(biomarker for immune cells of lymphoid or myeloid origin) indicated that these were leukocytes, of which many were macrophages or histiocytes positive for CD68.

CD3-positive T cells were less often seen( Figure 2G ).The numbers of leukocytes were more than 14 per square millimetre in the affected myocardial foci. These findings suggested that mice given IV mRNA COVID-19 vaccine can develop acute myopericarditis. Similar histopathological changes and severity were found in male mice(supplementary figure 2B,

A c c e p t e d M a n u s c r i p t 9

To determine if apoptosis was induced in cardiomyocytes, TUNEL immunofluorescent staining was used for detection of DNA fragmentation in apoptotic cells( Figure 3A ).

Apoptotic cardiomyocytes were significantly more often found in the IV group than IM group or NS group. Apoptotic cardiomyocytes distributed both sporadically or as large foci were found in 75% of IV group at 1dpi(6/8) and 38.5% at 2dpi(5/13) (p<0.05; Table 1, Figure   3B ).

To understand whether mRNA vaccine can transfect cardiomyocytes to express SARS-CoV-2 spike protein, we used immunostaining to detect SARS-CoV-2 S-RBD and showed occasional positive cardiomyocytes, infiltrating immune cells and vascular endothelial cells within the myocardium and pericardium in the IV but not IM vaccine or NS control group( Figures 4A, 4B, 4C ).. Using RT-qPCR [12] , the amount of COVID-19 mRNA Spike-RBD gene copies in heart tissues was significantly higher in IV than IM group at 1dpi(supplementary figure 3 ). Though no statistical significant differences were found, the mean amount of Spike-RBD mRNA was higher in IV than IM group at all other time points.

No grossly visible change of the heart in IM group was seen on autopsy or low power scan( Figure 5A ). H&E sections showed some myocardial vascular congestion and mild interstitial edema at 1dpi( Figure 5B ). Degenerative changes of cardiomyocytes were occasionally found at 2dpi( Figure 5B ). No obvious immune cell infiltration, cardiomyocyte A c c e p t e d M a n u s c r i p t 10 necrosis, or TUNEL-positive apoptotic cells were found at 1 or 2dpi( Figure 5C ). The changes were not sufficient to satisfy the histological criteria of myocarditis. Notably SARS-CoV-2 spike protein expression was only found in the infiltrating immune cells in the thigh muscle 1dpi in IM group. No degeneration, necrosis or SARS-CoV-2 protein expression was evident in the skeletal myocytes( Figures 5D, 5E ).

RT-qPCR assay showed increased mRNA expression of IFN-α/β, IL-6, TNF-α, CXCL10, CCL3 in heart tissue homogenates of the IV group, among which IFN-β, IL-6, and TNF-α were significantly higher at 2dpi than 1dpi( Figure 6A ). As for the IM group, all tested inflammatory cytokines/chemokines were transiently upregulated in heart tissues at 1dpi, and then decreased at 2dpi( Figure 6B ). But IL-1 β expression was significantly higher in cardiac tissues of male than female mice at 2dpi(supplementary figure 2A ).

Beads-based multiplex cytokine/chemokine flow cytometry assay showed that the IM group had significantly higher serum concentrations of cytokines/chemokines at 1dpi which decreased at 2dpi( Figure 6C ). Increased serum cytokine/chemokine concentrations were found in the IV group at 1dpi, but only CXCL10 and CCL5 were significantly higher than the NS control group( Figure 6C ). Enzyme immunoassay showed that serum troponin levels of IV group (1328.2+325.8pg/ml) was significantly higher than IM group (237.5+121.2pg/ml) and NS group(215+115.9pg/ml). (p<0.0001; Table 1) A c c e p t e d M a n u s c r i p t 11 Histopathological Changes of the Heart at 7dpi and 14dpi after First Dose, and at 2

At 7dpi, the heart of mice in IV group showed persistent changes of myopericarditis( Figure   7A ), while IM group only showed vascular congestion, myocardial edema and occasional foci of cardiomyocyte degeneration( Figure 7A ). At 14dpi, 4/6 (66.7%) of the mice in IV group showed grossly visible white patches over the visceral pericardium, and 6/6(100%)

showed changes of myopericarditis, compared with only mild degenerative changes in IM group( Figure 7B ; Table 1 ).

Two days after the second dose of mRNA vaccine, 4/9(44.7%) and 2/6(33.3%) of the mice in IM/IV group and IV/IM group developed grossly visible white patches over the visceral pericardium, respectively. Both groups showed more diffuse and severe changes of myopericarditis with foci of mild myocardial haemorrhage which affected both right and left heart( Figure 7D ). Moreover, serum cytokine/chemokine levels by beads-based flow cytometry assay showed significantly increased IFN-, TNF-α and CXCL10 at 2dpi after IV boosting which suggested that IV vaccine increased inflammatory responses, while CCL2 was increased after both IV and IM boosting( Figure 7E ).

H&E-stained sections of the liver tissues of the IV group showed diffuse ballooning degeneration of hepatocytes and focal hepatocyte necrosis at 1 to 2dpi( Figure 8A ), while the liver tissues of IM group showed much milder changes without hepatocyte necrosis at 1 to 2dpi(Supplementary figure 1B) . SARS-CoV-2 spike RBD expression by immunostaining was occasionally seen in hepatocytes of the IV but not IM group( Figure 8B ). Except for some A c c e p t e d M a n u s c r i p t 12 vascular congestion in lungs, H&E stained sections of spleen, brain, and kidney at 1 to 2dpi were unremarkable(Supplementary figure 1C) .

In a Balb/c mouse model with both male and female mice, IV but not IM administration of COVID-19 mRNA vaccine induced a rapid onset of multifocal myopericarditis with elevated serum troponin, cardiomyocyte degeneration and changes of both necrosis and apoptosis, adjacent inflammatory infiltrate of mononuclear cells, interstitial edema, and visceral pericardial calcification within 2dpi. Moreover, the IL-1β, IFN-β, IL-6 and TNF-α expression levels generally increased significantly from 1dpi to 2dpi in the IV but not IM group. Overall, the findings have satisfied the Dallas and immunohistochemical criteria of myocarditis [13] . Similar to findings of cardiac magnetic resonance imaging in human myocarditis, the most prominent site of focal involvement was the pericardial side of atrial and ventricular walls [14] . Notably, the myopericarditis was subclinical and the changes persisted but did not progress within 14dpi. But these histopathological changes of myopericarditis deteriorated and became rather diffuse after the second dose boosting with either IV or IM administration 14 days after the first dose of priming. While Balb/c mice have been extensively used for modelling myocarditis due to viral, protozoal and autoimmune insults [15] , myocardial mineralization can occur spontaneously with age in inbred laboratory rodents. However, we have excluded this possibility by the demonstration of highly significant differences in the gross pathological and histological changes of myopericarditis between mice challenged by IV versus IM vaccine or NS control (Table   1 ) [16] . blowing out the vessel [6] . However this speculation also lacks supportive scientific evidence.

Another possibility of getting a high blood mRNA vaccine level is the rapid movement of the vaccine through the lymphatic system into the venous circulation. 

Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic

World Health Organization. WHO Coronavirus (COVID-19) Dashboard

COVID-19) Vaccinations: Share of people who received at least one dose of COVID-19 vaccine

Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices -United States

Reducing pain at the time of vaccination: WHO position paper

Epidemiology and Prevention of Vaccine-Preventable Diseases: The Pink Book

Blood Aspiration During IM Injection

Thrombocytopenia and splenic platelet directed immune responses after intravenous ChAdOx1 nCov-19 administration

Public Assessment Report Authorisation for Temporary SupplyCOVID-19 mRNA Vaccine BNT162b2(BNT162b2 RNA)concentrate for solution for injection

H7N9 influenza A virus activation of necroptosis in human monocytes links innate and adaptive immune responses

Impact of SARS-CoV-2 variant-associated RBD mutations 1 on the susceptibility to serum antibodies elicited by COVID-19 infection or vaccination

Development and Evaluation of Novel and Highly Sensitive Single-Tube Nested Real-Time RT-PCR Assays for SARS

A histopathologic definition and classification

Cardiovascular magnetic resonance assessment of human myocarditis: a comparison to histology and molecular pathology

Myocarditis in Humans and in Experimental Animal Models

Spontaneously occurring cardiovascular lesions in commonly used laboratory animals

M a n u s c r i p t